myomiR-dependent switching of BAF60 variant incorporation into Brg1 chromatin remodeling complexes during embryo myogenesis

Katarzyna Goljanek-Whysall*‡, Gi Fay Mok‡, Abdulmajeed Fahad Alrefaei, Niki Kennerley, Grant N. Wheeler and Andrea Münsterberg§

ABSTRACT

Myogenesis involves the stable commitment of progenitor cells followed by the execution of myogenic differentiation, processes that are coordinated by myogenic regulatory factors, microRNAs and BAF chromatin remodeling complexes. BAF60a, BAF60b and BAF60c are structural subunits of the BAF complex that bind to the core ATPase Brg1 to provide functional specificity. BAF60c is essential for myogenesis; however, the mechanisms regulating the subunit composition of BAF/Brg1 complexes, in particular the incorporation of different BAF60 variants, are not understood. Here we reveal their dynamic expression during embryo myogenesis and uncover the concerted negative regulation of BAF60a and BAF60b by the muscle-specific microRNAs (myomiRs) miR-133 and miR-1/206 during somite differentiation. MicroRNA inhibition in chick embryos leads to increased BAF60a or BAF60b levels, a concomitant switch in BAF/Brg1 subunit composition and delayed myogenesis. The phenotypes are mimicked by sustained BAF60a or BAF60b expression and are rescued by morpholino knockdown of BAF60a or BAF60b. This suggests that myomiRs contribute to select BAF60c for incorporation into the Brg1 complex by specifically targeting the alternative variants BAF60a and BAF60b during embryo myogenesis, and reveals that interactions between tissue-specific non-coding RNAs and chromatin remodeling factors confer robustness to mesodermal lineage determination.

KEY WORDS: BAF chromatin remodeling complex, Brg1, miR-1, miR-206, miR-133, Smarcd, Chick embryo, Somite myogenesis

INTRODUCTION

Myogenesis in vertebrate embryos serves as a paradigm for cell fate commitment. The signals leading to the activation of myogenic regulatory factors (MRFs) in vivo, in the myotome of developing somites, are well characterized (Mok and Sweetman, 2011). Following myogenic commitment, a hierarchy of transcription factors controls the myogenic program (Bajard et al., 2006; Buckingham and Rigby, 2014). An important feature of muscle development and regeneration is post-transcriptional gene regulation by microRNAs (miRNAs), which are short non-coding RNAs that bind to target sites within mRNAs typically located in 3’UTRs (Williams et al., 2009a; Goljanek-Whysall et al., 2012a). miRNAs act through inhibition of translation and promote the degradation of target transcripts (Bartel, 2009; Bethune et al., 2012), suggesting a role for miRNAs in conferring accuracy of developmental timing and in supporting cell fate decisions and tissue identity (Stark et al., 2005; Hornstein and Shomron, 2006; Mann et al., 2010; Ebert and Sharp, 2012).

In skeletal muscle, two highly conserved miRNA families, miR-1/206 and miR-133, play important roles in proliferation, differentiation and cell fate specification; therefore, they have been termed myomiRs (McCarthy, 2008; van Rooij et al., 2008). In vertebrate embryos, miR-206 expression is restricted to skeletal myoblasts in somites, limb buds and head muscles, whereas miR-1 and miR-133 are expressed in developing skeletal muscle and heart (Darnell et al., 2006; Sweetman et al., 2006, 2008). In somites and C2C12 myoblasts, MRFs regulate miR-1, miR-206 and miR-133 expression (Rao et al., 2006; Rosenberg et al., 2006; Sweetman et al., 2008). miRNA-mediated negative regulation of target mRNAs is important for myogenic differentiation of C2C12 myoblasts, and the sustained expression of some miR-1/206 targets results in the activation of non-myogenic programs (Goljanek-Whysall et al., 2012b). In developing embryos, miR-1 and miR-206 have been shown to facilitate myogenic differentiation through negative regulation of the paired-box transcription factor Pax3 in myogenic progenitor cells (Goljanek-Whysall et al., 2011). This interaction is recapitulated during the activation of adult muscle stem cells (Chen et al., 2010; Hirai et al., 2010).

Members of the miR-1/206 family are produced from the same primary transcripts as members of the miR-133 family. In addition, these miRNAs are produced from multiple genomic loci: three in mouse and human and four in chick, which makes genetic approaches in mice challenging. Individual deletion of miR-1-2 or miR-206 does not lead to an overt skeletal muscle phenotype in adult mice (Zhao et al., 2007; Williams et al., 2009b). However, the regenerative capacity of skeletal muscle is compromised and loss of miR-206 attenuates muscle degenerative phenotypes seen in models of amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy (DMD) (Williams et al., 2009b; Liu et al., 2012). Genetic deletion of miR-133a-1 and miR-133a-2 in muscle leads to an adult-onset centronuclear myopathy, which correlates with the dysregulation of dynamin 2 (DNM2). This illustrates the essential role of miR-133a in the maintenance of adult skeletal muscle structure and myofiber identity (Liu et al., 2011). In embryonic stem cells (ESCs), miR-1 and miR-133 promote mesoderm differentiation (Ivey et al., 2008), and transcriptomic analyses in...
Mammalian cells can express three variants of the BAF60 subunit, which are encoded by different genes: BAF60a (Smarcd1), BAF60b (Smarcd2) and BAF60c (Smarcd3). In mouse and zebrafish BAF60c is expressed in developing heart, somites and neural tube (Lickert et al., 2004; Lamba et al., 2008). BAF60c is essential for cardiac and skeletal myogenesis and promotes the activation of cardiac and skeletal muscle-specific genes, including muscle-specific miRNAs (Lickert et al., 2004; Ochi et al., 2008; Mallappa et al., 2010). During cardiogenesis, BAF60c interacts with the cardiac-specific transcription factor GATA4 (Lickert et al., 2004; Takeuchi and Bruneau, 2009), whereas during skeletal myogenesis BAF60c interacts with MyoD, a key regulator of myogenesis (Forcales et al., 2012). Different BAF60 variants are present in distinct mammalian BAF complexes (Wang et al., 1996); for example, BAF60a but not BAF60c is present in mouse ESCs (Ho et al., 2009). In muscle, incorporation of BAF60a or BAF60b into the BAF complex might inhibit its ability to respond to pro-myogenic signaling (Forcales et al., 2012), and we recently showed that BAF60b activates alternative, non-myogenic differentiation programs in C2C12 cells, including chondrogenesis and osteogenesis (Goljanek-Whysall et al., 2012b). BAF subunit composition produces biological specificity; however, the mechanisms regulating BAF/Brg1 complex assembly during embryonic muscle development are poorly understood.

Chromatin remodeling determines access to gene regulatory elements by the transcriptional machinery and is thus important for lineage determination, including myogenic specification. The BAF chromatin remodeling complexes are important in neural and skeletal muscle differentiation and consist of 11 core subunits (Kadam and Emerson, 2003; Puri and Mercola, 2012). Combinatorial assembly of alternative BAF subunits together with the ATPase Brg1 leads to diversity, which is proposed to confer functional specificity in both neural and skeletal muscle lineages (de la Serna et al., 2001; Lessard et al., 2007; Wu et al., 2009; Yoo and Crabtree, 2009).

RESULTS

BAF60 variants are dynamically expressed during somite development

To examine their role in myogenesis, we investigated the expression of BAF60a, BAF60b and BAF60c transcripts and protein in vivo using chick embryos from Hamburger–Hamilton (HH; Hamburger and Hamilton, 1992) stage 12 to 20 (Fig. 1A-C; supplementary material Fig. S1A,B). Prior to myotome formation (HH12), BAF60a, BAF60b and BAF60c proteins were detected throughout immature epithelial somites (Fig. 1A); peptide blocking experiments indicate antibody specificity (supplementary material Fig. S1C). Somites undergo complex morphogenesis and the dorsal part forms the epithelial dermomyotome, from which cells enter the myotome in successive waves and initiate myogenic differentiation (Gros et al., 2004). In maturing somites (HH20), BAF60a, BAF60b and BAF60c were all expressed in the myotome (Fig. 1B). Quantitative PCR (qPCR)
showed that relative transcript amounts were similar for all three BAF60 variants in epithelial somites isolated from HH12 embryos, whereas in differentiating somites from HH20 embryos BAF60c expression was increased and BAF60a and BAF60b were expressed at low levels (Fig. 1C).

To determine how differential expression of BAF60a, BAF60b and BAF60c variants in developing somites affects BAF/Brg1 complex composition, we performed co-immunoprecipitations (CoIPs) using antibody against the core subunit Brg1 (Simone et al., 2004; Forcales et al., 2012). In epithelial somites at HH12, which consist of unspecified lineage precursors, all three BAF60 subunits bound to Brg1 at comparable levels. In somites of HH20 embryos, where lineage commitment has begun, the amount of BAF60c protein that co-immunoprecipitated with Brg1 was increased, whereas the amounts of BAF60a and BAF60b variants present in the complex were decreased compared with HH12 (Fig. 1D; supplementary material Fig. S1D), indicating a switch in Brg1/BAF60 subunit composition during somite maturation.

Knockdown of BAF60c or targeted misexpression of BAF60a/BAF60b abrogates myogenesis

BAF60c is important for myogenic differentiation of C2C12 myoblasts (Forcales et al., 2012). To assess the requirement of BAF60c for embryo myogenesis we used a knockdown (KD) approach in somites from HH14-15. Somites were analyzed 24 h after electroporation of specific FITC-labeled antisense morpholinos (MOs). Electroporation of BAF60c-MO led to localized loss of myogenin, a skeletal muscle differentiation marker, indicating that myogenic differentiation was inhibited on the injected side (Fig. 2A,B). Expression of myogenin was unaffected in control-MO-injected somites (Fig. 2A,B) or in somites injected with BAF60a-MO or BAF60b-MO (supplementary material Fig. S2A,B). Western blot of pooled somites, which averages the amount of protein present across the tissue, showed reduced BAF60a, BAF60b and BAF60c proteins after injection of BAF60 MOs compared with non-injected somites and control-MO (Fig. 2C; supplementary material Fig. S2C). This suggests that BAF60a and BAF60b variants are dispensable for somite myogenesis and confirms the importance of BAF60c in this process, consistent with findings in mice in which BAF60c was shown to be important for cardiac and skeletal muscle development after siRNA KD (Lickert et al., 2004).

We next asked whether sustained expression of BAF60a and BAF60b adversely affects myogenesis. Epithelial somites were electroporated at HH14-15 with BAF60a or BAF60b expression vectors together with a trace amount of GFP plasmid, or with GFP plasmid alone, and analyzed after 24 h (Fig. 2D). Increased expression of BAF60a and BAF60b was confirmed by qPCR (supplementary material Fig. S2D,E). GFP electroporation alone had no effect on myogenic differentiation. By contrast, expression of myogenin was completely or partially reduced 24 h after targeted misexpression of BAF60a or BAF60b. Phenotypes of embryos were assessed after whole-mount in situ hybridization; selected embryos

![Fig. 2. MO knockdown of BAF60c or misexpression of BAF60a or BAF60b variants inhibits myogenesis.](image-url)

(A) Electroporation of BAF60c-MO or control-MO into somites on one side, followed by in situ hybridization for myogenin (purple) and detection of the FITC-coupled MO (red). Whole-mount views and sections show that BAF60c-MO led to localized myogenin loss (arrows and arrowheads), whereas control-MO had no effect. (B) Percentage of embryos with an effect on myogenin expression after BAF60c-MO injection. (C) Western blot of pooled somites shows reduced BAF60c protein levels in BAF60c-MO electroporated somites, when compared with control-MO or to somites from the non-injected side (–MO). MO electroporations are mosaic and images shown in A give a spatial resolution, whereas the western blot in C averages what occurs in all cells across the somite. (D) Whole-mount double in situ hybridization and sections show that misexpression of BAF60a or BAF60b variants in somites leads to localized loss of myogenin expression. Myogenin is in purple (arrows and arrowheads) and GFP transcripts, which are expressed from a separate, co-injected plasmid, are in red. The ratio of BAF60 expression plasmid to GFP expression plasmid is 5:1. (E) Myogenin expression phenotypes observed after electroporation. (F) qPCR shows reduced myogenin expression in somites electroporated with BAF60a or BAF60b expression vectors when compared with GFP plasmid controls. Material from multiple embryos was pooled. Error bars indicate s.d.; *P<0.05 (t-test). my, myotome; nt, neural tube; nc, notochord. Scale bars: 50 μm.
were processed for cryosections (Fig. 2D,E). Effects on myogenic differentiation were confirmed by qPCR of pooled transfected somites, which had reduced myogenin transcript levels compared with controls (Fig. 2F).

These results show that differential expression of BAF60 variants in embryonic somites is important for myogenic differentiation and indicate that sustained expression of BAF60a and BAF60b interferes with BAF60c function. Thus, we examined factors that might negatively regulate BAF60a and BAF60b in the developing myotome.

**BAF60a and BAF60b expression in developing somites is negatively regulated by myomiRs**

Alignments show that a putative miR-133 binding site, with a seed sequence conserved between chick (*Gallus gallus*, Gga), human (*Homo sapiens*, Hsa) and mouse (*Mus musculus*, Mmu), is present in the 3′ UTR of the *BAF60a* gene. A putative binding site for miR-1 or miR-206 was found in the 3′ UTR of the *BAF60b* gene, but here the seed sequence is less well conserved between the three species (Fig. 3A). *In situ* hybridization shows that mir-1, miR-206 and miR-133 are expressed in the myotome (Fig. 3B; see also Goljanek-Wyssall et al., 2011; Sweetman et al., 2008). This correlates with reduced *BAF60a* and *BAF60b* transcripts and with less BAF60a and BAF60b bound to Brg1 in differentiating somites (Fig. 1C,D). To test whether BAF60a and BAF60b are directly targeted by miR-133 and by miR-1 or miR-206 respectively, sensor constructs were generated with 3′ UTR fragments containing putative miRNA binding sites downstream of luciferase (Fig. 3C). Co-transfection of a BAF60a sensor with miR-133 led to downregulation of luciferase expression compared with co-transfection with miR-140, an unrelated miRNA not predicted to target the 3′ UTR. Similarly,
co-transfection of a BAF60b sensor with miR-1 or miR-206 led to downregulation of luciferase expression compared with controls. Point mutations introduced into the putative target sites rendered sensors non-responsive to the respective miRNAs (Fig. 3C). The chicken BAF60a 3′UTR sensor did not respond to miR-1 or miR-206, and the BAF60b 3′UTR sensor did not respond to miR-133 (supplementary material Fig. S3C).

To examine the regulation of endogenous BAF60a and BAF60b transcripts by miRNAs in a physiological context and in a different species we used mouse NIH3T3 cells, which express all BAF60 variants (supplementary material Fig. S3B), but do not express the myomiRs miR-133, miR-1 or miR-206. Western blots show that transfection with miR-133 led to reduced BAF60a protein compared with control cells, and co-transfection of antimiR-133 restored BAF60a protein levels to that of controls (Fig. 3D). Transfection with miR-1 or miR-206 or both miRNAs led to reduced BAF60b protein compared with control cells, and co-transfection with antimiR-206, which inhibits both miR-1 and miR-206 (Goljanek-Whysall et al., 2011), restored BAF60b protein levels to that of controls (Fig. 3D). The effect of miR-133 or a combination of miR-1 and miR-206 on transcript levels of all BAF60 variants was also examined by qPCR. This confirmed that miR-133 transfection led to reduced BAF60a expression but did not affect the levels of the other two variants. Similarly, miR-1/206 transfection resulted in lower levels of endogenous BAF60b expression without affecting BAF60a or BAF60c. Expression of BAF60c was unaffected by miR-133 or miR-1/206 (supplementary material Fig. S3B).

**Inhibition of miR-133 or miR-1/miR-206 abrogates myogenesis and alters BAF/Brg1 subunit composition**

We next examined the consequences of antagomir-mediated inhibition of miRNA function for both embryo myogenesis and BAF60a and BAF60b expression levels. The function of miR-133 or miR-1/miR-206 was inhibited by injection of specific antagomirs into somites of HH14-15 embryos, which were analyzed after 24 h. Northern blots of pooled somites showed that antagonist-133 inhibited miR-133 expression (supplementary material Fig. S4A). We previously showed that antagonist-1 or antagonist-206 specifically inhibits miR-1 or miR-206, respectively (Goljanek-Whysall et al., 2011). Furthermore, PCR experiments showed that antagonist-1 and antagonist-206 led to loss of miR-1 and miR-206, but had no effect on miR-133; and antagonist-133 specifically affected miR-133 and had no effect on miR-1 or miR-206 (supplementary material Fig. S4B,C). Inhibition of miR-1 or miR-206 at this stage led to partial loss of myogenin expression in the majority of embryos as compared with the contralateral control (Fig. 4A,B). Simultaneous inhibition of both miR-1 and miR-206 led to a significant number of embryos with complete loss of myogenin expression (Fig. 4B, third column). Because of this more prominent phenotype, we used a combination of antagonist-1 and antagonist-206 in all further experiments.

We next analyzed the effects of miR-133 inhibition in maturing somites. Interestingly, antagonist-mediated inhibition of miR-133 in somites led to complete loss of myogenin expression in the majority of embryos (85%). In addition, somite morphology was altered and both dermomyotome and myotome were poorly defined (Fig. 4A,B fourth column). Injection of scrambled antagonist had no effect on embryo myogenesis (Fig. 4B, seventh column; supplementary material Fig. S4D). qPCR analyses of pooled somites injected with specific antagonirs demonstrated significantly reduced myogenin expression compared with non-injected or scrambled-injected control somites (Fig. 4C). Inhibition of all three myomiRs in developing somites led to loss of myogenin expression in the majority of embryos after 24 h (Fig. 4B, fifth column). After 48 h, myogenin was still impaired in embryos injected with a combination of antagomirs (antagonir-1, -206 and -133) even though effects were less severe (Fig. 4B, sixth column). This indicates a role for myomiRs in controlling entry into the myogenic differentiation program during embryogenesis.

Next we investigated the regulation of BAF60a and BAF60b expression by myomiRs in vivo. Specific antagonirs inhibiting miR-133 or miR-1/206 were injected into somites on one side of the embryo at HH14-15. We then examined BAF60a and BAF60b transcript and protein levels. Non-injected somites from the contralateral side and scrambled antagomir-injected somites served as controls. Microinjection of antagonist-133 led to increased BAF60a transcript and protein levels in somites compared with controls (Fig. 4D,E). Microinjection of either antagonist-1 or antagonist-206, or a mixture of both antagonirs, led to increased BAF60b transcript and protein levels compared with controls (Fig. 4F,G).

Finally, we examined whether increased BAF60a and BAF60b protein levels, after antagonist-mediated inhibition of miR-133 or miR-1/206, altered the composition of BAF/Brg1 complexes. To assess whether relative amounts of BAF60 variants were affected, we performed CoIPs using anti-Brg1 antibody. In antagonist-133-injected somites, the amount of BAF60a found in a complex with Brg1 increased and less BAF60c co-precipitated compared with non-injected somites. The amount of BAF60b protein detected after CoIP was similar in control and antagonist-133-injected somites (Fig. 4H, compare lanes 1, 2). Input lanes showed a relative increase in BAF60a protein after antagonist-133 injection (Fig. 4H, compare lanes 7, 8). Inhibition of both miR-1 and miR-206 with antagonirs led to an increase in the amount of BAF60b protein that interacted with Brg1, when compared with the non-injected somites. BAF60c was detected at reduced levels in the complex after antagonist-1/206 injection (Fig. 4H, compare lanes 3, 4). Input showed a relative increase in BAF60b after antagonist-1 and -206 injection (Fig. 4H, compare lanes 9, 10). Injection of scrambled antagonist did not affect the levels of BAF60 variants that co-immunoprecipitated with Brg1, when compared with non-injected somites (Fig. 4H, compare lanes 5, 6). Input samples for scrambled antagonist are shown (Fig. 4H, compare lanes 11, 12). A similar CoIP experiment, including a negative control, is shown in supplementary material Fig. S4E. These data suggest that miR-133, miR-1 and miR-206 affect the composition of BAF/Brg1 chromatin remodeling complexes through post-transcriptional regulation of BAF60a and BAF60b variants during somite differentiation.

**Antagonir-induced inhibition of myogenesis can be restored by MO knockdown of BAF60a or BAF60b**

Next we examined whether BAF60a or BAF60b KD using MOs could rescue the antagonist-induced loss of myogenin in developing somites. Somites of HH14-15 embryos were injected with antagonist-133 or with antagonist-1 plus antagonist-206 and co-injected and electroporated with either control-MO or with specific BAF60a-MO (after antagonist-133 injection) or BAF60b-MO (after antagonist-1/206 injection) and analyzed after 24 h. All MOs were FITC labeled and electroporation led to a mosaic distribution. To determine the effects on differentiation, myogenin expression was examined by in situ hybridization. As before, embryo myogenesis was inhibited after antagonist-mediated inhibition of myomiRs in the presence of control-MO (Fig. 5A,B top panels, 5C). However, expression of myogenin was partly restored in the presence of
antagomir when BAF60a or BAF60b was knocked down using specific MOs (Fig. 5A,B bottom panels, 5C). These results indicate that, following myotome formation and myoblast commitment, miR-133 and miR-1/206 negatively regulate BAF60a and BAF60b variants by preventing the translation of residual transcripts expressed in progenitors at earlier developmental stages. We propose that this then allows the commencement of the myogenic differentiation program in the somite myotome by affecting the composition of Brg1 chromatin remodeling factors and, in particular, the incorporation of BAF60 variants (Fig. 6).

DISCUSSION
Mammalian BAF chromatin remodeling complexes are involved in cell differentiation and reprogramming. Together with transcription factors, BAF complexes govern cell lineage decisions, and subunit composition is thought to determine specificity. However, it is not clear how complex assembly is controlled during tissue development and embryogenesis (Wu et al., 2009; Puri and Mercola, 2012). Here, we reveal the expression of BAF60 variants in embryonic somites and uncover the negative regulation of BAF60a and BAF60b by the myomiRs miR-1/206 and miR-133 during the commitment and differentiation of embryonic myoblasts. We identify the chromatin remodeling factor BAF60a as an important target for miR-133 and show that BAF60b is an important target for miR-1/206, not only in myogenic C2C12 cells (Goljanek-Whysall et al., 2012b) but also in embryonic myoblasts in developing somites. Interference with myomiR function following myoblast commitment led to changes in BAF60a and BAF60b expression levels in somites, a concomitant switch in BAF subunit composition in vivo and delayed myogenic differentiation. Thus, the concerted negative regulation of BAF60a...
and BAF60b levels by the myomiR families is crucial to enable BAF60c-driven myogenic differentiation in the maturing myotome.

An important role has been identified for ATP-dependent chromatin remodeling during the initiation of muscle differentiation, and dominant-negative chromatin remodeling enzymes block MyoD-mediated myogenic differentiation of NIH3T3 fibroblasts (de la Serna et al., 2001). These effects correlated with changes in myogenin promoter chromatin structure and with altered expression levels of a number of other muscle differentiation genes (de la Serna et al., 2005). Thus, it will be interesting to determine how different BAF60 variants affect the activity of the Brg1 complex, its binding to muscle-specific transcription factors and effects on chromatin structure at native muscle promoters.

BAF60c is important for cardiac and skeletal myogenesis (Lickert et al., 2004; Ochi et al., 2008; Forcales et al., 2012) and has been shown to play a role during smooth muscle differentiation (Sohni et al., 2012). miRNA-mediated regulation provides a mechanism by which the composition of the BAF/Brg1 complex can be controlled at the post-transcriptional level during skeletal muscle development. Interestingly, miRNA-mediated exchange of BAF variants was described during neuronal differentiation, where BAF53a is downregulated by miR-9* and miR-124 (Yoo et al., 2009). This suggests that miRNA-regulated switching of BAF subunit composition might be a common regulatory mechanism in both myogenic and neurogenic lineages. A similar circuitry has recently been revealed in fibro-adipogenic cells (FAPs) in postnatal muscle. Treatment with HDAC inhibitors led to upregulation of MyoD, BAF60c and myomiRs, which affected the levels of BAF60a and BAF60b variants and altered FAP myogenic potential (Saccone et al., 2014).

Exploiting the accessibility of the chicken embryo for in vivo manipulations, we previously identified a crucial role for miR-206 during the transition of myogenic progenitors to committed myoblasts. We showed that negative regulation of the pro-myogenic, paired-box transcription factor Pax3 ensures robust execution of this developmental program in early somites (HH12) (Goljanek-Whysall et al., 2011). The present study extends this work to assess the role of the miR-1/206 and miR-133 cluster in later somite differentiation (HH14-15). We propose that these muscle-specific miRNAs, which are activated by MRFs (Rao et al., 2006; Rosenberg et al., 2006; Sweetman et al., 2008), serve to stabilize the

Fig. 5. Knockdown of BAF60a or BAF60b restores myogenesis after miRNA inhibition. (A) Somites injected with AM133 were electroporated with FITC-labeled control-MO or BAF60a-MO, as indicated. In situ hybridization for myogenin transcripts (purple) and detection of FITC-MO (red) shows that myogenic differentiation is inhibited in the presence of AM133 plus control-MO (top row, arrows and arrowheads); whole-mount and section are shown. Co-electroporation of BAF60a-MO with AM133 rescued the expression of myogenin (bottom row). (B) Somites injected with AM1 plus AM206 were electroporated with FITC-labeled control-MO or BAF60b-MO, as indicated. In situ hybridization for myogenin transcripts (purple) and detection of FITC-MO (red) shows that myogenic differentiation is inhibited in the presence of AM1 and AM206 plus control-MO (top row, arrows and arrowheads). Myogenin expression is rescued when BAF60b-MO is co-electroporated with AM1 and AM206 (bottom row, arrows and arrowheads). Scale bar: 50 µm. (C) Summary of phenotypes observed after AM/MO injections. my, myotome; nt, neural tube; nc, notochord.

Fig. 6. Model illustrating the expression and regulation of BAF60 variants in embryonic somites by myomiRs. (A) All BAF60 variants are expressed throughout epithelial somites. The coloring indicates different cell lineages; the ventral half contains chondrogenic progenitors (blue) and the dorsal half contains myogenic progenitors (red). (B) In differentiating somites miR-133, miR-1 and miR-206 are expressed in the myotome (green), which is generated from the edges of the dermomyotome (red), as indicated by arrows. We propose that myomiRs decrease the levels of BAF60a and BAF60b protein available to bind to Brg1, thus allowing an increase in BAF60c to be incorporated into the BAF/Brg1 complex. This switch in complex composition permits activation of myogenic differentiation in embryonic myocytes. The continued presence of high levels of BAF60a and BAF60b variants interferes with myogenic differentiation, presumably by displacing BAF60c from the Brg1 chromatin remodeling complex. ES, epithelial somites; DML, dorsomedial lip; VLL, ventrolateral lip; DM, dermomyotome; MY, myotome; NT, neural tube; NC, notochord; SC, sclerotome.
differentiation program of committed myoblasts (Fig. 6). This is achieved through targeting of crucial genes, including Pax3 and BAF60a/b, which are associated with progenitor states of muscle cells or with potential alternative differentiation paths.

Consistent with the latter, previous work showed that sustained expression of BAF60b in C2C12 myogenic cells inhibited skeletal muscle differentiation and enabled the expression of genes associated with alternative, non-myogenic lineages, including chondrogenesis and osteogenesis (Goljanek-Wyssal et al., 2012b). Interestingly, BAF60a, but not BAF60c, has been shown to be present in ESC BAF (esBAF) complexes, which are required for self-renewal and pluripotency of mouse ESCs (Ho et al., 2009). Moreover, BAF60a was shown to be a part of a BAF complex in cardiac progenitors and suggested to be exchanged for BAF60c during cardiac differentiation (Chen et al., 2012). Here we demonstrate that targeted misexpression of BAF60a or BAF60b variants or antagonim-mediated inhibition of miRNA function in somites inhibited myogenic differentiation of committed myoblasts. Antagonim injection led to a specific increase of either BAF60a or BAF60b, in terms of both protein and transcripts (Fig. 4D-G; supplementary material Fig. S4F), and this affected the BAF/Brg1 complex composition, potentially by displacement of BAF60c from Brg1. However, additional cross-regulation of BAF60a, BAF60b and BAF60c expression cannot be excluded at present.

miRNAs and their targets are often expressed in a mutually exclusive fashion (Hornstein and Shomron, 2006; Ebert and Sharp, 2012). During somite development, BAF60a, BAF60b and BAF60c are expressed in the epithelial somite. The epithelial somite undergoes dramatic reorganization and differentiates into the dermomyotome and myotome, with the dermomyotome layer containing the progenitors, which will translocate into the myotome (Gros et al., 2004). During somite differentiation, all BAF60 variants were detected in the myotome (Fig. 1B) and qPCR revealed an increase in BAF60c in older somites compared with BAF60a and BAF60b (Fig. 1C). CoIPs showed an increased amount of BAF60c bound to Brg1 compared with BAF60a and BAF60b (Fig. 1D), suggesting a shift in BAF/Brg1 complex composition during somite differentiation. Our data indicate that myomiR inhibition interferes with this process (Fig. 4H; supplementary material Fig. S4E), possibly through derepression of BAF60a and BAF60b transcripts present in the myotome.

It has been shown that BAF60c directly interacts with MyoD in both undifferentiated and differentiating C2C12 myoblasts. In response to p38 signals, the BAF complex is recruited to activate the transcription of muscle genes (Forcales et al., 2012). We show here for the first time that the amount of BAF60a and BAF60b variants bound to Brg1 decreases during somite differentiation, and our experiments suggest that negative post-transcriptional regulation, mediated by miR-1/206 and miR-133, is necessary for the timely progression of myogenic differentiation. The data support the idea of a BAF60 variant switch during embryonic myogenesis. We show that BAF60a and BAF60b are dispensable for myogenic differentiation in vivo (supplementary material Fig. S2A,B), and their elevated expression in developing somites led to changes in BAF/Brg1 complex composition and adversely affected differentiation (Fig. 2D-F, Fig. 4H; supplementary material Fig. S4E). MO-mediated rescue experiments suggest that, at this stage in development, delayed myogenin expression induced by myomiR inhibition is largely related to elevated levels of BAF60a and BAF60b (Fig. 5). It remains to be established whether this correlates with structural chromatin changes at the myogenin promoter (de la Serna et al., 2001, 2005).

Chicken BAF60a and BAF60b 3′UTR sensor constructs containing target sites for either miR-133 or miR-1-206 were efficiently targeted by miR-133 or miR-1-206 (Fig. 3C; supplementary material Fig. S3C). In mouse NIH3T3 cells, endogenous BAF60a and BAF60b expression was regulated by the myomiRs at the level of protein and RNA (Fig. 3D; supplementary material Fig. S3B), suggesting effects on both mRNA stability and repression of protein translation. Interestingly, the miR-1 and miR-206 seed sequences are not well conserved in the 3′ UTR of human and mouse BAF60b (Fig. 3A). This indicates species-specific differences and suggests the presence of non-canonical miR-1/206 target sites in mouse and human. Non-canonical miRNA binding sites use additional complementary nucleotides outside the seed sequence, are widespread and are able to regulate gene expression (Loeb et al., 2012).

BAF60c, together with the cardiac transcription factors Gata4 and Tbx5 can direct the ectopic differentiation of mouse mesoderm into beating cardiomyocytes. Interestingly, BAF60b was able to replace BAF60c in this assay, although BAF60b was less efficient at driving reprogramming (Takeuchi and Bruneau, 2009). In skeletal muscle, BAF60b has been proposed to have an ‘ancillary’ function to BAF60c (Puri and Mercola, 2012) and both variants have been identified as MyoD-interacting proteins in yeast two-hybrid assays (Forcales et al., 2012), suggesting a degree of redundancy. Our data support the role of BAF60c as the ‘master’ BAF60 variant necessary for muscle differentiation. It remains possible that BAF60a and BAF60b variants are important in progenitors. Their expression in somites is consistent with this, and it will be interesting to determine which factors associate with BAF60a- and BAF60b-containing complexes in progenitors and early myoblasts. It remains to be seen which genes are regulated by these complexes during lineage specification; but it is clear that negative regulation of BAF60a and BAF60b variants is important. The loss of negative regulation led to impaired myogenesis in embryos.

Our results are consistent with the proposed function of miRNAs in the fine-tuning of genetic programs (Hornstein and Shomron, 2006; Ebert and Sharp, 2012) and suggest that the coordinated downregulation of BAF60a and BAF60b variants by myomiRs provides robustness to the muscle differentiation program through effects on Brg1/BAF60 variant composition. It appears that this is not only important in embryo myogenesis, but also postnatally, when it can affect the myogenic potential of FAPs (Saccone et al., 2014).

MATERIALS AND METHODS
DNA constructs, transfections and luciferase assay
Sensor constructs contained chick BAF60a or BAF60b 3′UTR fragments in a modified pGL3 vector (Promega); for primers see supplementary material Table S1 and Goljanek-Wyssal et al. (2011). Mutant constructs had BamHI or SalI sites within miR-1/206 or miR-133 target sites. Chick dermal fibroblasts (DF1) were transfected with 200 ng plasmid with or without miRNAs (50 nM) (Sigma) using Lipofectamine 2000 (Invitrogen) in 96-well plates. miRNA mimics were identical to endogenous miRNAs; for sequences see supplementary material Table S1. pGL3 vector without 3′UTR or with mutant 3′UTRs, or the transfection of unrelated miR-140, served as a negative control. Transfections employed triplicate samples and were repeated four times using independent plasmid preparations. Firefly and Renilla luciferase activities were measured after 48 h using a multi-label counter (Victor2, PerkinElmer) and relative activities were calculated. Mouse BAF60a and BAF60b expression vectors (MRC Geneservice) and GFP plasmid were used for targeted misexpression in vivo at a ratio of 5:1.

Cell culture, western blot and qPCR
Mouse NIH3T3 cells in DMEM, 10% FBS, 1% pen/strep were transfected with miR-206, miR-1 or miR-133 (50 nM; Sigma) with and without antimiRs (100 nM; Ambion) using Lipofectamine 2000. Mock-transfected
cells served as controls. Protein was extracted after 48 h and 20 μg was run on 8-12% polyacrylamide gels and blotted onto PVDF membrane. Primary antibodies (Abcam) to BAF60α (1:500; ab83208), BAF60β (1:1000; ab81622), BAF60c (1:500; ab50556), Brg1 (1:500; ab110641) and actin (1:1000; ab3220) were applied at 4°C overnight; secondary antibodies (Dako, P0447; and Jackson ImmunoResearch, 111-035-003) were applied for 1 h at room temperature.

RNA was isolated with TRizol (Invitrogen). cDNA synthesis used SuperScript II reverse transcriptase (Invitrogen) with 1 μg RNA (cells) or 400 ng RNA (somes). For miRNA qPCR, the MysticQ miRNA cDNA Synthesis Kit (Sigma) was used. Primers (supplementary material Table S1), miRNA primers (designed by Sigma) and SYBR Green MasterMix (Applied Biosystems, Sigma) were used with the Applied Biosystems 7500 Fast Real-Time PCR System following the manufacturer’s protocols. All qPCR was normalized to beta-actin (miRNA) or RNU-6 (miRNA).

**In situ hybridization and immunohistochemistry**

Whole-mount *in situ* hybridization using double DIG-labeled LNA oligos (Exonig) or antisense RNA probes was carried out as previously described (Goljanek-Whysall et al., 2011). Probes detecting BAF60 variants were designed to overlap 3′ UTR regions to ensure specificity. Embryos were fixed in 4% paraformaldehyde, embedded in O.C.T. Compound (Sakura Finetek), sectioned and immunostained as described (Goljanek-Whysall et al., 2011). Primary antibodies (Abcam; see above) were used at 1:100 dilution and incubated at 4°C overnight; secondary antibody (Molecular Probes, A11008) was used at 1:500 dilution. DAPI (Sigma) was used to stain cell nuclei (1:10,000 dilution).

**Injection of antagonom and MoS**

Antagonomers (Dharmacon) were designed based on published methods (Goljanek-Whysall et al., 2011). All bases were 2′O-methyl thiol bonds replaced phosphodiester bonds between bases 1-2, 2-3, 19-20, 20-21 and 21-22; 3′ cholestrol was added. Scrambled sequences were used as controls [final concentration 1 mM, except when mixed with MoS (1:1) in rescue experiments]. The posterior six somites of HH14-15 embryos were injected. Embryos were harvested after 24 h and injected somites and somites from the un.injected side were dissected and lysed. Somites from 20-25 embryos were pooled for western blot analysis; three biological repeats used material from independent experiments. BAF60 MoS were 3′ FITC labeled (Gene Tools) (supplementary material Table S1). Control MoS do not target any known gene. MoS were injected into somites at HH14-15 and embryos were electroporated using six 10 msec pulses of 60 V. Embryos were harvested after 24 h for analyses. Mouse BAF60α or BAF60β expression vectors mixed with a GFP plasmid in a 5:1 ratio or GFP expression vector alone were electroporated as described for MoS.

**Co-immunoprecipitation**

Somites of non-treated HH12 or HH20 embryos were dissected and lysed. Somites from embryos injected at HH14-15 with antagonomers were dissected after 24 h, pooled and lysed in 20 mM HEPES (pH 7.4), 150 mM NaCl, 10% glycerol, 1% Triton X-100 on ice for 15 min. We obtained 20 μg protein from untreated somites and 10 μg from antagonist-injected somites. The supernatant was split for immunoprecipitation (40%), input (20%) and resuspended in 10 μl 1× Laemmli buffer, boiled and run on 8-12% polyacrylamide gel (Bio-Rad), followed by western blot.

**Acknowledgements**

We thank Marlene Jahnke for assistance with molecular cloning and Paul Thomas for expert support with microscopy.

**Competing interests**

The authors declare no competing financial interests.

**Author contributions**

K.G.-W., G.F.M., A.F.A. and N.K. performed experiments. K.G.-W., G.F.M. and A.M. designed experiments, discussed and analyzed data. A.M. directed the research, K.G.-W., G.F.M. and A.M. wrote the manuscript.

**Funding**

miRNA and muscle research were funded by Biotechnology and Biological Sciences Research Council (BBSRC) project grants to A.M. [BB/H019979, BB/K003437]. A.F.A. was supported by a PhD studentship from Saudi Arabia [U360]. Deposited in PMC for immediate release.

**Supplementary material**

Supplementary material available online at http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.108787/-/DC1

**References**


Fig. S1. Expression of BAF60 variants in developing somites. In situ hybridization using specific antisense RNA probes against the divergent 3’UTR of BAF60a, -b, and -c is shown. (A) Transcripts encoding all three variants are detected in epithelial somites of HH12 embryos. (B) In differentiating somites of HH20 embryos, BAF60a, -b and -c transcripts are detected in the myotome (my). (C) For peptide blocking, primary antibodies (Abcam; see Materials and Methods) were used at 1:500 dilution and mixed with 1 μg/ml peptide (Covalab; see supplemental table 1). Antibody/peptide mixtures were incubated overnight at 4°C. Immunohistochemistry was then performed as stated in materials and methods. When BAF60a antibody was incubated with BAF60a peptide, or BAF60b antibody was incubated with BAF60b peptide, or BAF60c antibody was incubated with BAF60c peptide (indicated by *) there was a complete loss of signal in the neural tube and myotome. When BAF60a, -b and -c antibodies were incubated with other peptides, signal was present in the neural tube and myotome. All images were exposed for the same mount of time. Cell nuclei stained with DAPI (blue) and the BAF60 variants stained in green. Scale bars 50 μm. (D) CoIP using Brg1 antibody and protein isolated from HH12 or HH20 somites shows that the amount of BAF60a and BAF60b protein bound to Brg1 decreases over time, whereas the amount of BAF60c variant associated with Brg1 increases in differentiating somites. IgG antibody-only samples were used as negative control. nt, neural tube; nc, notochord; so, somite; dm, dermomyotome.
Fig. S2. Knock-down of BAF60a or BAF60b does not affect myogenin expression. (A) Double whole mount in situ hybridization for myogenin (purple, arrows and arrowheads) and detection of FITC-labeled morpholinos (red) against BAF60a or BAF60b, as indicated. Sections show myogenin expression on the MO-injected side is largely unaffected compared to the contralateral side. (B) Summary of myogenin phenotypes observed after MO injections: green, normal; red, reduced. In some embryos reduced expression was observed. (C) Western blot of protein extracted from somites injected with control-MO or BAF-MO as indicated, -MO indicates non-injected, contralateral somites. Reduced levels of BAF60a protein were seen after BAF60a-MO injection; reduced levels of BAF60b protein were observed after BAF60b-MO injection. Electroporation of MOs is mosaic and not all cells are affected, the WB indicates the average across the pooled tissue. (D) qPCR detecting increased amounts of BAF60a transcripts in somites electroporated with BAF60a expression construct along with a GFP tracer (ratio of 5:1) compared to contralateral non-injected somites. No increase was seen in GFP only electroporated somites. Error bars are SD (*P<0.05, T-test). (E) qPCR detecting increased amounts of BAF60b transcripts in somites electroporated with BAF60b expression construct along with a GFP tracer (ratio of 5:1) compared to contralateral, non-injected somites. Injection and electroporation of GFP only served as control and no effect on BAF60b transcripts was observed Error bars are SD (*P<0.05, T-test).
Fig. S3. myomiRs regulate expression of BAF60 variants in mouse NIH3T3 cells. (A) Alignment of the putative miR-133 target site in the 3'UTRs of chick (*Gallus gallus*, Gga), human (*Homo sapiens*, Hsa) and mouse (*Mus musculus*, Mmu) BAF60a gene. Nucleotides complementary to the respective miR are colored red. The human (h-mir-133) and mouse (m-mir-133) sequences contain an additional uracil at the 5' end, which is complimentary to the target sequence. (B) qPCR of mouse NIH3T3 cells for BAF60a, BAF60b, or BAF60c. Cells were mock transfected (blue) or transfected with miR-1 and miR-206 (red) or with miR-133 (green). The expression of endogenous BAF60a was affected by miR-133, but not by miR-1 and miR-206. The expression of endogenous BAF60b was affected by miR-1 and miR-206, but not by miR-133. The expression of endogenous BAF60c transcripts was not affected by transfection of myomiRs. Error bars are SD (*P<0.05, T-test). (C) Luciferase sensors containing 3'UTR sequences of chick BAF60a or BAF60b were transfected into DF-1 cells. Transfection of miR-133 led to a significant down-regulation of luciferase expression from the BAF60a 3'UTR sensor compared to controls, however transfection of miR-1 and miR-206 had no effect. Transfection of a non-related miRNA, miR-140, served as a negative control. Point mutations in the putative target site rendered the sensor non-responsive to miR-133 Error bars are SD (*P<0.05, T-test). Co-transfection of miR-1 and miR-206 led to significant down-regulation of luciferase expression from the BAF60b 3'UTR sensor compared to controls, however transfection of miR-133 had no effect. Transfection of a non-related miRNA, miR-140, served as a negative control. Point mutations in the putative target site rendered the sensor non-responsive to miR-1 and miR-206.
Fig. S4. Antagomir-133 and antagomir-1/206 downregulate miR-133 and miR-1/206 respectively and results in upregulation of BAF60a and BAF60b transcript and protein. (A) Northern blot of somites injected with scrambled antagomir (AMscr) or with antagomir-133 (AM133), both indicated with (+), shows specific effects on miR-133. Contralateral non-injected somites are shown, indicated by (-). (B) qPCR detecting miR-1 (blue) or miR-206 (red) in somites injected with antagomirs as indicated. AM1 and AM206 resulted in almost complete loss of miR-1 and miR-206, but expression of these miRNAs was not affected by AM133 or AMscr. (C) qPCR detecting miR-133 in somites injected with antagomirs as indicated. AM133 significantly reduced miR-133 expression, however AM1/206 or AMscr had no effect. Error bars are SD (*P<0.05, T-test). (D) Section of somites injected with AMscr shows that there is no effect on the expression of myogenin after 24 hours. Myogenin (purple) is detected by in situ hybridization using antisense RNA probe. The FITC-labeled AM is detected using an anti-FITC antibody coupled to alkaline phosphatase (red). Scale bar 50 mm. my, myotome; nt, neural tube; nc, notochord. (E) CoIP using anti-Brg1 antibody or IgG only as negative control. Somites were injected with relevant antagomirs, AM1 and AM206, or AM133, as indicated. After 24 hours somites were dissected together with non-injected somites from the opposite side (Ctrl) for protein lysis. Western blot detected similar Brg1 amounts in all lanes. More BAF60a protein and less BAF60c protein were pulled down with Brg1 after AM133 injection; more BAF60b protein and less BAF60c protein was pulled down with Brg1 after injection with AM1 and AM206. This suggests that myomiR inhibition affects BAF/Brg1 complex composition. (F) qPCR for transcripts of BAF variants expressed in somites after injection with relevant antagomirs. AM133 led to an increase of BAF60a transcripts, but AM1/206 or AMscr did not. AM1/206 led to an increase of BAF60b transcripts, but AM133 or AMscr did not. BAF60c transcript levels in embryonic somites were not affected by any of the antagomirs injected. Error bars are SD (*P<0.05, T-test).
Table S1: microRNA mimics, primers, morpholinos and peptides

<table>
<thead>
<tr>
<th>miR</th>
<th>Mimics</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-1</td>
<td>5’-UGGAUAAGUAAAGAAGUAUGUA-3’</td>
</tr>
<tr>
<td></td>
<td>5’-CAUACUUUUAUAGCCCAAUA-3’</td>
</tr>
<tr>
<td>miR-206</td>
<td>5’-UGGAUAAGUAGGAGUGUGUGGU-3’</td>
</tr>
<tr>
<td></td>
<td>5’-ACAUGCUUCAAUAUAAUUGCCCAAUA-3’</td>
</tr>
<tr>
<td>miR-133</td>
<td>5’-UUUGUCUCCCAUCAACCAGCU-3’</td>
</tr>
<tr>
<td></td>
<td>5’-AGCUUGGUAAGGAACCAAAAAU-3’</td>
</tr>
<tr>
<td>miR-140</td>
<td>5’-AGUGGUUUUACCCUAUGGUAG-3’</td>
</tr>
<tr>
<td></td>
<td>5’-CCACAGGGUAGAACCAGGGAC-3’</td>
</tr>
<tr>
<td>chBAF60a RT F</td>
<td>GCGGCCTATCGGAGACAGAG</td>
</tr>
<tr>
<td>chBAF60a RT R</td>
<td>GCCCGAGCAGTTCGAGTCAG</td>
</tr>
<tr>
<td>chBAF60b RT F</td>
<td>CCAAAGGTCCAGGACGTCG</td>
</tr>
<tr>
<td>chBAF60b RT R</td>
<td>TGGGGCGGGAGGAGATCAGG</td>
</tr>
<tr>
<td>chBAF60c RT F</td>
<td>AGTCAGCGGCTACATGGG</td>
</tr>
<tr>
<td>chBAF60c RT R</td>
<td>TCCCTTCTTTCATTCAAG</td>
</tr>
<tr>
<td>chBeta-actin RT F</td>
<td>CCAGCTGGGAGGAGCGG</td>
</tr>
<tr>
<td>chBeta-actin RT R</td>
<td>CTGGGCAACAGCCGGCTT</td>
</tr>
<tr>
<td>chMyogenin RT F</td>
<td>GCCATTCAGATACGAGCG</td>
</tr>
<tr>
<td>chMyogenin RT R</td>
<td>CTCAGAGGTGATCCTCGG</td>
</tr>
<tr>
<td>mBAF60a RT F</td>
<td>GGTCCAAAATCGAACAAATCACAG</td>
</tr>
<tr>
<td>mBAF60a RT R</td>
<td>GGACCAGTTCGCAATCTT</td>
</tr>
<tr>
<td>mBAF60b RT F</td>
<td>CTTCTGAGGCGATGAGGGTA</td>
</tr>
<tr>
<td>mBAF60b RT R</td>
<td>ATGCCAGAGCGCTGTACT</td>
</tr>
<tr>
<td>mBAF60c RT F</td>
<td>AACGCAGGGCTGAGTCTAC</td>
</tr>
<tr>
<td>mBAF60c RT R</td>
<td>CTGGGCAACAGCCGGCTT</td>
</tr>
<tr>
<td>mBeta-actin RT F</td>
<td>GATCAAGATCATTGCTCCTG</td>
</tr>
<tr>
<td>mBeta-actin RT R</td>
<td>AGGGTGTAAATCGCAGCT</td>
</tr>
<tr>
<td>chBAF60a 3’UTR F</td>
<td>AGATCTGCCTGATCTCCTCCT</td>
</tr>
<tr>
<td>chBAF60a 3’UTR R</td>
<td>GCCCCCATTTGCTGCAGCAAAAGA</td>
</tr>
<tr>
<td>chBAF60b 3’UTR F</td>
<td>AGATCTGCTGCTGATCTCCT</td>
</tr>
<tr>
<td>chBAF60b 3’UTR R</td>
<td>GCCCCCATTTGCTGCAGCAAAAGA</td>
</tr>
<tr>
<td>chBAF60a probe F</td>
<td>GCCCTCACATTCCCTC</td>
</tr>
<tr>
<td>chBAF60a probe R</td>
<td>AGGAGGCAAGCTGCTTGACAG</td>
</tr>
<tr>
<td>chBAF60b probe F</td>
<td>CGTACCCTGGGCTGCCCTC</td>
</tr>
<tr>
<td>chBAF60b probe R</td>
<td>GCCAGAGGGCTGCTGAGCG</td>
</tr>
<tr>
<td>chBAF60c probe F</td>
<td>CCTAGCCTGGCAGAGGCTAT</td>
</tr>
<tr>
<td>chBAF60c probe R</td>
<td>TCAAGTCTGGGGAATCGACAG</td>
</tr>
<tr>
<td>BAF60a Morpholino (translation blocking)</td>
<td>GCCGCCATTTGCTGCAGCAAAAGA</td>
</tr>
<tr>
<td>BAF60b Morpholino (e2i2 splice junction target)</td>
<td>GCTGGCGTGCTGACCTCTC</td>
</tr>
<tr>
<td>BAF60c Morpholino (splice junction targets)</td>
<td>TGTGGCTTACCTTCCATACCTT</td>
</tr>
<tr>
<td>Control Morpholino</td>
<td>CTCCTATACCTCAATTATA</td>
</tr>
<tr>
<td>cBAF60a peptide</td>
<td>RKLRIFISNTFNPASDAEDGEVTASWLEVGLLEDALSKYDATQ</td>
</tr>
<tr>
<td>cBAF60b peptide</td>
<td>SNNPQDFIQEWIKSSRLKIITDIGNPEERRAEFYQQPWAQEA</td>
</tr>
<tr>
<td>cBAF60c peptide</td>
<td>FERKLDQ1MRKRVDEQALEKRPMQKQKRRLYISNTFNPASDADDSDG</td>
</tr>
</tbody>
</table>